That was a far worse decline than the 19% loss by the biotech sector, in general, as measured by the iShares Nasdaq Biotechnology ETF While Alnylam’s share price was weak through the first nine months of the year, investors can mostly chalk that up to the general sell-off in biotech. However, the company’s stock was decimated in October after the company reported a major clinical setback.